1. Introduction
Orally disintegrating tablets (ODTs) are solid dosage forms designed to disintegrate rapidly in the oral cavity without the need for water, offering improved patient compliance, especially for pediatric, geriatric, and dysphagic populations [
1]. Rapid disintegration and fast drug release are the key performance attributes of ODTs, and these properties are strongly influenced by the choice of excipients and manufacturing techniques [
2]. Among the various manufacturing approaches, direct compression (DC) is widely preferred due to its simplicity, cost-effectiveness, minimal processing steps, and compatibility with heat- and moisture-sensitive drugs. However, successful DC of ODTs requires excipients with carefully balanced functional properties such as good flowability, adequate compressibility, and the ability to promote rapid tablet disintegration [
3].
To achieve these requirements, co-processed excipients have emerged as a promising strategy. Co-processing improves the functionality of individual components without altering their chemical structure, producing composite particles with synergistic behavior [
4]. A common design principle for direct compression is to combine a plastic deforming material with a brittle fracturing material. Plastic excipients undergo extensive deformation under pressure, enabling strong interparticulate bonding and high tablet tensile strength. However, their compressibility is often highly sensitive to magnesium stearate, because the formation of a lubricant film reduces interfacial bonding. In addition, plastic materials tend to exhibit decreased tablet hardness at high tableting speeds, as slower stress relaxation limits bond formation [
5]. In contrast, brittle materials fragment upon compression, generating fresh surfaces that contribute to bonding and thus reduce sensitivity to lubricants. Their fragmentation mechanism also allows more consistent compressibility at high tableting speeds, providing improved robustness during industrial-scale manufacturing [
6]. Combining these two deformation mechanisms within a single co-processed system therefore offers a balanced approach, yielding an excipient with enhanced compressibility, adequate flowability, and improved performance under varying manufacturing conditions [
7].
Starch is commonly characterized as a plastically deforming material with limited fragmentation, yet it exhibits good swelling and wicking properties that contribute effectively to tablet disintegration [
8]. In contrast, sugars such as lactose and mannitol behave as brittle materials and typically enhance packing efficiency and flowability due to their higher density [
9]. They also improve patient acceptability, as these sugars contribute to a more pleasant taste profile, particularly mannitol which imparts a mild sweetness and a characteristic cooling sensation that is desirable in ODT formulations [
10]. These complementary mechanical and functional attributes make starch–sugar combinations well suited for direct compression and ODT applications, as demonstrated by several commercially available co-processed excipients [
11].
While existing co-processed systems perform effectively in many formulations, opportunities remain to further tailor particle porosity, wetting behavior, and microstructural design for enhanced ODT performance. Many traditional manufacturing techniques such as spray drying or conventional drying of wet granules provide limited control over internal pore architecture or require energy-intensive processing [
12,
13]. Optimizing the balance between granule hardness, porosity, and disintegration efficiency can therefore be challenging, especially when attempting to optimize excipient performance across a broader range of formulation needs or APIs.
Microwave-assisted wet granulation offers additional advantages as a flexible and efficient method for engineering excipient functionality. Wet granulation improves powder cohesiveness, enhances flowability, and promotes uniform distribution of moisture, producing granules with better packing and compressibility [
14]. When combined with microwave irradiation, the technique provides rapid and accelerated moisture evaporation inside the granules, which generates internal vapor pressure that promotes controlled pore formation and microstructural expansion [
15]. This mechanism is particularly beneficial for starch-based systems, as microwave-induced vapor channels can create porous starch structures that enhance water uptake and accelerate disintegration [
15,
16]. Through this combined effect can be effectively adjusted in a single processing step. In addition, the technique is considered a green technique, offering reduced processing times and compatibility with commercial-scale continuous or batch microwave systems.
Therefore, this study aimed to develop and characterize a microwave-assisted wet-granulated co-processed excipient composed of rice starch (RS) and mannitol for direct compression of ODT formulations. The effects of microwave energy and processing duration on physicochemical properties, powder functionality, and excipient performance were systematically investigated. Furthermore, the optimized formulation was incorporated into ODTs containing chlorpheniramine maleate and piroxicam, representing BCS class I and class II drugs, respectively, and its performance was compared with a commercial co-processed excipient (Starlac®) and physical mixture controls. Altogether, the findings highlight the promise of microwave-assisted co-processing as a green, efficient, and scalable approach for producing high-performance excipients tailored for direct compression in ODT manufacturing.
2. Materials and Methods
2.1. Materials
Native rice starch (RS) (Lot No. 709161) was obtained from Thai Flour Industry Co., Ltd. (Bangkok, Thailand). Mannitol (CAS No. 1344-09-8; Product Code 2305169781) was sourced from Kemaus (Cherrybrook, NSW, Australia). Chlorpheniramine maleate (CPM) (Lot No. SLL/C/0624070) was purchased from S. Tong Chemicals Co., Ltd. (Nonthaburi, Thailand), and piroxicam (Lot No. PRAH0360518) was supplied by Apex Healthcare Limited (Gujarat, India). Starlac® (Meggle GmbH, Wasserburg, Germany) (Lot No. L104262421A535) was supplied by Thai Meochems Co., Ltd. (Bangkok, Thailand).
2.2. Preparation of Co-Processed Rice Starch with Mannitol Using Microwave-Assisted Wet Granulation Technique (MW-RM)
RS and mannitol were co-processed using a microwave-assisted wet granulation technique. RS and mannitol powders at a weight ratio of 1:2 were blended using a mortar and pestle following the geometric dilution method. The batch size for each preparation was 50 g. Deionized (DI) water was gradually added to the mixture (0.3 mL/g of dry powder) and mixed until a suitable wet mass was formed. The wet mass was passed through a No. 16 sieve to produce wet granules. The wet granules were then subjected to microwave treatment using a microwave oven (model: R-219EX(K), Sharp Thai, Bangkok, Thailand) under varying conditions of microwave power (440, 620, and 800 W) and treatment time (15, 30, 45, and 60 s) (
Table 1). During microwave treatment, the wet granules were uniformly spread as a thin powder bed on a flat glass plate to ensure homogeneous microwave exposure, and no mechanical mixing or agitation was applied during irradiation. The microwave-treated granules were subsequently dried in a hot air oven for 6 h, passed through a No. 20 sieve, and stored in an airtight container until further analysis. The control samples were prepared, which included pure RS and mannitol granules prepared under the lowest (440 W, 15 s) and highest (800 W, 60 s) microwave conditions, as well as co-processed RS–mannitol (1:2) prepared by conventional wet granulation without microwave treatment (W-RM). In addition, the commercial co-processed excipient Starlac
®, composed of approximately 85% alpha-lactose monohydrate and 15% native maize starch (
w/
w), was included as a positive control.
2.3. Scanning Electron Microscope (SEM)
Morphological analysis was carried out with a CLARA field emission scanning electron microscope (FESEM; TESCAN, Brno, Czech Republic). Samples were pretreated at 60 °C for 24 h prior to observation. Imaging was performed under low-vacuum conditions (0.7–0.8 Torr) using an accelerating voltage between 10 and 20 kV.
2.4. Particle Size and Size Distribution
Particle size and distribution were analyzed using a laser diffraction method (Malvern Mastersizer S, Malvern Instruments, Malvern, UK). Before measuring, samples were dried at 60 ± 5 °C for 24 h. The analysis was conducted by wet dispersion in methanol (refractive index 1.33), with starch assigned a refractive index of 1.53. Particle size parameters (D10, D50, D90, D4,3, and span) were recorded, and span values were calculated according to Equation (1). All measurements were carried out in triplicate.
2.5. Fourier Transform Infrared (FT-IR) Spectroscopy
FT-IR spectra were recorded using an Invenio R spectrophotometer (Bruker, Billerica, MA, USA). The samples were dried at 60 °C for 24 h before measurement and subsequently mixed with potassium bromide (KBr) powder to obtain a fine dispersion. The analysis was carried out in attenuated total reflectance (ATR) mode.
2.6. X-Ray Diffraction (XRD)
The crystallinity of the samples was evaluated using X-ray diffraction (XRD). Diffraction patterns were recorded on a Miniflex II diffractometer (Rigaku, Tokyo, Japan) operated in reflection mode. Data were collected over a 2θ range of 5–60° at a scan speed of 2.5°/min to obtain the characteristic diffraction profiles.
2.7. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) was performed using a DSC-1 instrument (Mettler-Toledo, Greifensee, Switzerland). Samples were heated from 25 to 250 °C at a rate of 10 °C/min. The characteristic transition temperatures, including onset (To), peak (Tp), and end (Te), as well as the peak area, were recorded. The enthalpy change (ΔH) was calculated and expressed in J/g of sample weight.
2.8. Powder Density
Powder bulk and tapped densities were determined using the graduated cylinder method in accordance with the standard USP method [
17]. Sample powder (50 g) was gently poured into a graduated cylinder (1 mL readability), and the initial volume was recorded as the bulk volume. Bulk density was calculated as the ratio of powder mass to bulk volume. For tapped density, the cylinder was placed on a jolting volumeter (Stav 2003, Erweka, Langen, Germany) and tapped repeatedly for 1250 times to obtain the final tapped volume was then used to calculate tapped density. The test was repeated in triplicate.
True density was measured with an Accupyc II 1340 pycnometer (Micromeritics, Norcross, GA, USA) based on the principle of helium gas displacement. The sample powder was weighed into a sample cup, and measurements were performed at 25–30 °C over ten cycles. The instrument automatically calculated true density from the powder mass and the displaced volume. The test was repeated ten times.
2.9. Surface Area, Pore Volume, and Pore Size Analysis
The surface and pore characteristics of the samples were determined using a nitrogen adsorption–desorption method on a BET surface analyzer (Nova2200e, Quantachrome, Boynton Beach, FL, USA). All samples were degassed under vacuum at 80 °C for 5 h to remove adsorbed gases. The specific surface area (SSA) was calculated using the multipoint Brunauer–Emmett–Teller (BET) equation, while pore characteristics were determined according to BJH method.
2.10. Moisture Content and Hygroscopicity
Moisture content was measured using a moisture analyzer (MX-50, A&D, Tokyo, Japan). Sample powder (1.000 g) was accurately weighed and analyzed at 105 °C until a constant mass was achieved, indicating complete removal of volatile components. The moisture content was expressed as the percentage mass loss, and each determination was conducted in triplicate.
Hygroscopicity was evaluated following a pre-drying step in a hot-air oven at 80 °C for 12 h to eliminate residual moisture. Subsequently, 250 mg of the dried sample was transferred into a pre-weighed sample cup (2.5 cm diameter). The cups were placed inside a sealed tight container containing a saturated sodium chloride solution to maintain a relative humidity of 75%. After storage for 7 days, the samples were re-weighed, and hygroscopicity was calculated as the percentage increase in mass. All measurements were conducted in triplicate.
2.11. Powder Flowability
Powder flowability was evaluated according to USP guidelines using the angle of repose (AR) and compressibility index (CI). The AR was measured using a fixed-funnel method with a funnel orifice diameter of 12 mm and a funnel height of 10 cm above the base. Sample powder (50 g) was allowed to flow freely through a funnel positioned at a constant height above a flat surface, forming a conical bulk without external vibration. The height (h) of the powder cone and the base radius (r) were measured, and the angle of repose (θ) was calculated using Equation (1). Bulk and tapped densities were measured as described previously, and the CI was calculated using Equation (2). The test was repeated in triplicate.
2.12. Compression Behavior
The compaction performance of the powders was investigated with respect to plastic deformation, particle rearrangement, tensile strength, solid fraction, and resulting tablet porosity. For this purpose, tablets were prepared by compressing 250 mg portions of each sample using a hydraulic press (Model C, Carver, Wabash, IN, USA) equipped with an 8.4 mm flat-faced round die. To minimize sticking and lower ejection forces, pre-lubrication was performed by applying a thin layer of a 1% (w/v) magnesium stearate suspension in acetone to the punch faces and die wall using a cotton swab, followed by complete evaporation of the solvent prior to compression. Compression was carried out at four pressure levels (49, 98, 147, and 196 MPa), and the resulting tablets were evaluated for weight, thickness, and diameter. The test was repeated at least in triplicate.
2.12.1. Plastic Deformation Property
The plastic deformation of the powders was evaluated through Heckel analysis, which assumes that densification during compression follows first-order kinetics. According to this model, the relative density (D) of the compact increases proportionally with the applied pressure (P), as expressed in Equation (3). The material’s plasticity is characterized by its yield pressure (Py), derived from the slope of the Heckel plot, with lower Py values indicating greater plasticity [
18].
where D denotes the relative density at a given pressure P. The intercept (A) reflects initial particle rearrangement and volume reduction during die filling. The constant
k, obtained from the linear regression slope of the Heckel plot, is used to calculate the yield pressure (Py), defined as the reciprocal of
k.
2.12.2. Particle Rearrangement
Particle rearrangement during compaction was assessed using relative density parameters derived from compression data. The relative density at die filling (ρ
0) was defined as the ratio of bulk density to true density, representing the efficiency of initial packing under gravity. The relative density after the initial stage of compression (ρA) was calculated from the intercept (A) of the Heckel plot, as shown in Equation (4). A further parameter, ρB, was used to describe additional particle rearrangement and potential fragmentation occurring in the early phase of compression, as given in Equation (5).
2.12.3. Tablet Tensile Strength, and Solid Fraction
Tablet hardness was measured using a PTB-311 hardness tester (Pharmatest, Hainburg, Germany) and the values were used to calculate tensile strength, solid fraction (SF), and porosity (ε) according to Equations (6)–(8).
where σx represents tablet tensile strength (Mpa), and X corresponds to the measured hardness (N). The parameters d and t denote tablet diameter (mm) and thickness (mm), respectively. Wt is the tablet weight,
ρtrue is the true density of the powder, and V is the apparent tablet volume. The solid fraction (SF) reflects the relative density of the compact, while porosity (ε) represents the proportion of void space within the tablet structure.
2.12.4. Elastic Recovery
Elastic recovery (ER) was assessed based on the time-dependent relaxation of tablets following compression. Tablets were prepared according to the previously described procedure. The initial tablet volume was measured immediately after ejection and recorded as V
ej. Subsequently, the tablets were stored in a tightly sealed container for 24 h, after which the volume was remeasured and denoted as V
24h. The ER (%) was calculated using Equation (9). The test was repeated in triplicate.
2.13. Lubricant Sensitivity
The sample powders were blended with magnesium stearate powder (1%
w/
w) for 15 min to evaluate the effect of lubrication. Subsequently, 250 mg of each blend was compressed into tablets using a hydraulic press at a compression pressure of 98 MPa. The tablet hardness was determined using a tablet hardness tester, and the lubricant sensitivity ratio (LSR) was calculated according to Equation (10). The test was repeated at least in triplicate.
where T
0 and T
1 represent the tablet hardness values of unlubricated and lubricated compacts, respectively.
2.14. Disintegration Property
Disintegration property of the samples was determined using disintegration test and wetting test. The sample powder (250 mg) was compressed into a tablet using a hydraulic press (Model C, Carver, Wabash, IN, USA) fitted with an 8.4 mm flat-faced round die under a compression pressure of 98 MPa.
2.14.1. Disintegration Test
The disintegration time was evaluated for six tablets using a basket-rack assembly of a disintegration tester (PTZ Auto 3, PharmaTest, Hainburg, Germany). Each tablet was placed in an individual tube of the basket, and the test was performed in 750 mL of distilled water maintained at 37 ± 0.5 °C. The time required for each tablet to disintegrate completely was recorded as the disintegration time. According to the European Pharmacopoeia (Ph. Eur.), tablets with a disintegration time of not more than 3 min are classified as ODTs [
19]. Measurements were conducted using six tablets per formulation.
2.14.2. Wetting Test
The wetting time of the tablets was determined using a simple visual method. Three circular Whatman No. 5 filter papers (47 mm in diameter) were evenly placed in a watch glass, and 2 mL of distilled water was added to uniformly moisten the papers. Each tablet was carefully positioned on the filter paper, and the time required for the liquid to completely cover and moisten the upper surface of the tablet was recorded as wetting time. The test was repeated in triplicate.
2.14.3. Water Absorption Ratio
The water absorption ratio (%) was determined to evaluate the liquid uptake capacity of the tablets. Each tablet was initially weighed, and the dry weight was recorded as Wi. The tablets were then placed on Whatman No. 5 filter papers moistened with distilled water until complete wetting was achieved. Afterward, the filter papers containing the fully wet tablets were weighed to obtain the total wet weight (Ww). The weight of the dry filter paper (Wp) and the amount of water absorbed by the filter paper alone (Wwp) were determined separately under identical conditions. The water absorption ratio was calculated using the following Equation (11). The test was repeated in triplicate.
where Ww is the total weight of the filter paper and wetted tablet, Wp is the weight of the dry filter paper, Wwp is the amount of water absorbed by the filter paper, and Wi is the initial tablet weight.
2.15. Contact Angle Measurement
The surface wettability of the tablets was evaluated by measuring the static contact angle using an Optical Contact Angle Meter (Theta Flow, Biolin Scientific, Gothenburg, Sweden). The sample powder (250 mg) was compressed into tablets without lubricant using a hydraulic press (Model C, Carver, Wabash, IN, USA) equipped with an 8.4 mm flat-faced round die under a compression pressure of 98 MPa. A droplet of glycerol (5 µL) was carefully dispensed onto the tablet surface using an automated syringe system. The contact angle was recorded 10 s after droplet deposition using a high-resolution camera equipped with OneAttension software Version 4.2.1 (r10106) (Biolin Scientific). The contact angle was determined from the average of three independent measurements on different areas of tablet surface. The test was repeated in triplicate.
2.16. Formulation Study
The functionality of MW-RM as a direct compression excipient for orally disintegrating tablets (ODTs) was evaluated using two model drugs including chlorpheniramine maleate (CPM) and piroxicam. These model drugs represented BCS class I and class II drugs, respectively. Each model drug was incorporated at a fixed dose of 4 mg per tablet for CPM and 20 mg per tablet for piroxicam. Each model drug was blended with the excipient (MW-RM-H-30 or Starlac®) for 15 min to ensure homogeneity, followed by the addition of magnesium stearate (1% w/w) and further mixing for 2 min. The resulting powder blend was then compressed into tablets using a single punch tablet press (CMT 12, Charatchai, Bangkok, Thailand). Flat faced punches with diameters of 6.3, and 8.0 mm were used for preparing CPM and piroxicam tablets, respectively. For comparison, physical mixture formulations were prepared by blending each model drug with RS and mannitol in the same proportion as used in the MW-RM composition.
The quality attributes of the CPM and piroxicam tablets which including weight variation, hardness, friability, and disintegration were evaluated in accordance with the United States Pharmacopeia (USP). Ten tablets were individually weighed to assess weight variation, and another ten tablets were tested for tablet breaking force using a tablet hardness tester. Approximately 6.5 g of tablets were used to determine friability with a friability tester (PTF 20ER, Pharmatest, Hainburg, Germany) [
20]. Disintegration testing was performed on six tablets using a basket rack apparatus with purified water maintained at 37 ± 0.5 °C as the disintegration medium [
21]. The drug content was determined in accordance with the USP specification, which requires the content to be within 90–110% of the labeled amount for CPM and piroxicam tablets [
22], and within 92.5–107.5% for piroxicam tablets [
23]. All analyses were at least conducted in triplicate.
2.17. In Vitro Release Study
The dissolution testing of CPM and piroxicam tablets was performed using a USP Apparatus II (SR8PLUS Dissolution Test Station, Hanson Research, Chatsworth, CA, USA) (paddle method) under standard conditions. For CPM, six tablets were tested in 500 mL of 0.01 N hydrochloric acid (pH approximately 2) maintained at 37 ± 0.5 °C with a paddle rotation speed of 50 rpm. At predetermined time points (1, 3, 5, 10, 15, and 30 min), 5 mL of dissolution medium was withdrawn and immediately replaced with fresh medium to maintain sink conditions. The samples were analyzed using a UV-Vis spectrophotometer (UV2600i, Shimadzu, Kyoto, Japan) at 265 nm. The release profile was assessed based on the USP requirement that not less than 80% (Q) of chlorpheniramine maleate should dissolve within 30 min. For piroxicam tablets, six units were evaluated in 900 mL of 0.01 N hydrochloric acid at 37 ± 0.5 °C and 50 rpm. Samples of 5 mL were collected at the same designated time points and replaced with fresh medium. The drug concentration was determined at 333 nm using the same spectrophotometric system. Compliance with the USP specification was established if not less than 75% (Q) of the labeled amount of piroxicam dissolved within 45 min.
2.18. Statistical Analysis
All experiments were performed at least in triplicate, and the results are presented as mean ± standard deviation. Statistical analysis was conducted using one-way analysis of variance (ANOVA) in SPSS software (Version 19.0; IBM Corp., Armonk, NY, USA). When significant differences were detected, post hoc comparisons were carried out using Tukey’s Honestly Significant Difference (HSD) test at a 95% confidence level (p < 0.05).
4. Conclusions
This study successfully developed a novel co-processed excipient composed of rice starch (RS) and mannitol (MW-RM series) using a microwave-assisted wet granulation technique. The approach effectively combined the plastic deformation behavior of starch with the brittle fracture characteristics of mannitol, while microwave treatment introduced particle porosity that enhanced its performance as a direct-compression excipient for ODT formulations. The influence of microwave energy and treatment duration was systematically evaluated to optimize functional properties of the co-processed materials.
SEM analysis showed the transformation of irregular starch granules and elongated mannitol crystals into a more spherical, and cohesive agglomerated of materials. Particle size analysis demonstrated granule enlargement following wet granulation and subsequent size reduction due to microwave-induced structural shrinkage. True density and porosity data confirmed the formation of internal porous structures in the MW-RM-H series, which is favorable for rapid liquid penetration during disintegration. FTIR and DSC analyses demonstrated no chemical interactions and preserved thermal properties, while XRD results indicated partial amorphization that may further promote fast wetting and dissolution.
These physicochemical improvements indicated excellent manufacturability of the MW-RM powders. The optimized formulation, MW-RM-H-30, exhibited superior flowability, appropriate compressibility, and rapid disintegration as confirmed by standardized disintegration testing. In addition, MW-RM-H-30 demonstrated short wetting time, high water absorption capacity, and reduced contact angle compared with the non-microwave-treated material, indicating enhanced surface wettability and more efficient liquid penetration into the tablet matrix. When formulated into ODTs containing CPM and piroxicam as model drugs, MW-RM-H-30 enabled the production of tablets meeting pharmacopeial criteria for friability, content uniformity, and drug content, while maintaining rapid disintegration performance. Dissolution studies further confirmed that MW-RM-H-30 tablets achieved similar release profiles to Starlac®, a commercial benchmark excipient, and significantly faster dissolution than the physical mixture. These findings confirm that MW-RM-H-30 fulfills essential requirements for direct-compression ODT applications.
Overall, the microwave-assisted wet granulation represents an efficient and promising manufacturing strategy for producing rice starch–based co-processed excipients with enhanced pharmaceutical performance. Nevertheless, potential scale-up challenges related to non-uniform microwave energy distribution and moisture gradients should be considered. Future work will therefore focus on long-term stability studies, systematic scale-up evaluation, and broader API compatibility to support the industrial translation of this excipient platform.